RECOMBINANT ENVELOPE PROTEIN HIV1 F2 RGP120 WITH MF59

含有 MF59 的重组包膜蛋白 HIV1 F2 RGP120

• 批准号: 6115603
• 负责人: BARNEY S GRAHAM
• 金额: $ 3.64万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115603
• 关键词: AIDS therapy; AIDS vaccines; CHO cells; HIV envelope protein gp120; clinical research; clinical trial phase I; drug screening /evaluation; human immunodeficiency virus 1; human subject; human therapy evaluation; immunomodulators; recombinant proteins; vaccine development; vector vaccine

The objective of this study is to determine the safety and immunogenicity of an improved two-vial formulation of CHO cell-derived HIV-1 SF-2 rgp120 envelope vaccine formulated with MF59 adjuvant emulsion when administered to healthy HIV-1 uninfected volunteers. Prior formulations had suboptimal stability or were impractical (requiring storage at -70 degrees C). Therefore, an improved formulation has been developed that is expected to be more practical and stable, to allow studies of this expanded vaccine candidate or analogous candidates designed for other geographic regions.Our goal is recruitment of sufficient volunteers and following their long term progress.

本研究的目的是确定其安全性和免疫原性